New drug combo trial aims to outperform standard lung cancer treatment
NCT ID NCT07183189
Summary
This large, late-stage trial is testing whether adding a new drug called SHR-A2009 to the standard treatment (aumolertinib) works better for people with a specific type of advanced lung cancer. It will involve 576 adults who have not yet received treatment for their advanced cancer. The main goal is to see if the combination can keep the cancer from growing for a longer time compared to the standard drug alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Guangdong Provincial People's Hospital
RECRUITINGGuangzhou, Guangdong, 510080, China
Contact
Conditions
Explore the condition pages connected to this study.